AZ14289671 is a highly selective and blood-brain barrier penetrant irreversible TKI that targets EGFRExon20 insertions
Aisha M. Swaih(The Francis Crick Institute), Nicolas Floc’h(AstraZeneca (United Kingdom))
Cited by 0
Related Papers
No related papers found
Powered by citation graph analysis